PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Calcitonin→

Calcitonin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
9007-12-9
Molecular formula
C151H226N40O45S3
Molecular weight
3417.9 g/mol
Drug class
Peptide hormonecalcitonin receptor agonist and inhibitor of osteoclastic bone resorption
Mechanism of action
Binds calcitonin receptors on osteoclasts, reducing osteoclast activity and bone resorption. It also has effects on renal calcium and phosphate handling; clinical use depends on formulation and jurisdiction.
Indications / reported uses
  • Short-term treatment of hypercalcaemia when other measures are inadequate
  • Treatment of Paget disease of bone in selected patients when alternative therapies are unsuitable
  • Selected osteoporosis indications in some jurisdictions; long-term use is restricted or discouraged in certain products because of safety concerns

Sources: US DailyMed — Calcitonin-salmon products · EMA — Calcitonin-containing medicines review · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Calcitonin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Calcitonin Permitted Daily Exposure (PDE) report (the Calcitonin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Calcitonin Occupational Exposure Limit (OEL) report (the Calcitonin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.